Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
CRL - Charles River Laboratories International, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$267.60
DETAILS
HIGH:
$300.00
LOW:
$219.00
MEDIAN:
$273.00
CONSENSUS:
$267.60
DOWNSIDE:
7.24%
Stock News
Is This the Right Time to Add CRL Stock to Your Portfolio?
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
Contrasting Charles River Laboratories International (NYSE:CRL) and IB Acquisition (NASDAQ:IBAC)
Charles River Laboratories International (NYSE: CRL - Get Free Report) and IB Acquisition (NASDAQ: IBAC - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Earnings and Valuation This table compares
Wall Street Is Now Backing the Clarity Act. Here's the Most Likely Scenario for What Happens Next With Crypto.
According to prediction markets, final passage of the Clarity Act is not likely to happen until mid-2027 at the earliest. If the Clarity Act stalls out in Congress, the crypto industry will need to rely on favorable rule making from the likes of the SEC, CFTC, and OCC.
Great Lakes Advisors LLC Makes New $459,000 Investment in Charles River Laboratories International, Inc. $CRL
Great Lakes Advisors LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,026 shares of the medical research company's stock, valued at approximately $459,000. A
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
Charles River Gains 88.6% in a Year: What's Driving the Rally?
CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.
John Rogers Trims Sphere Entertainment Co (SPHR) -- Stock Still 106% Overvalued on GF Value
On June 30, 2026, John Rogers (Trades, Portfolio), through Ariel Investment, LLC, executed a significant reduction in the firm's position in Sphere Entertainmen
John Rogers Trims Lindblad Expeditions Holdings Inc (LIND) Stake -- Shares Remain Significantly Overvalued on GF Value
On June 30, 2026, John Rogers (Trades, Portfolio), through Ariel Investment, LLC, executed a reduction of the firm's position in Lindblad Expeditions Holdings I
John Rogers Buys Core Laboratories Inc (CLB) -- Shares Look 28% Undervalued on GF Value
On June 30, 2026, John Rogers (Trades, Portfolio), founder of Ariel Investment, LLC, increased the firm's stake in Core Laboratories Inc (NYSE: CLB) by 904,557 s
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC's next-generation multivalent.
Charles River Laboratories International (NYSE:CRL) CAO Michael Gunnar Knell Sells 6,645 Shares
Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) CAO Michael Gunnar Knell sold 6,645 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the sale, the chief accounting
Charles River Laboratories International (NYSE:CRL) Sets New 52-Week High – Still a Buy?
Shares of Charles River Laboratories International, Inc. (NYSE: CRL - Get Free Report) hit a new 52-week high on Tuesday. The company traded as high as $277.07 and last traded at $276.34, with a volume of 1025310 shares trading hands. The stock had previously closed at $267.49. Analyst Ratings Changes CRL has been the subject
International Markets and Charles River (CRL): A Deep Dive for Investors
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
Charles River Laboratories International Q2 Earnings Call Highlights
Charles River Laboratories International NYSE: CRL reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earnings and free-cash-flow guidance while maintaining a cautious view that the recovery in biopharmaceutical demand will progress gradually.
Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript
Charles River Laboratories International, Inc. (CRL) Q2 2026 Earnings Call Transcript
CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market
Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.
Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?
Here is how Charles River Laboratories (CRL) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Charles River: Near-Term Inflection But Long-Term Risk
Charles River Laboratories has rebounded 40% from last year, driven by improved organic revenue and a positive inflection in order trends. CRL raised guidance, now expecting slightly positive organic growth and EPS of $11.15–$11.45, with margin expansion locked in through divestitures and cost cuts. Segment performance is mixed: DSA shows strong backlog and book-to-bill, while RMS faces U.S. weakness offset by China strength; manufacturing margins benefit from divestitures.
Price Targets
Charles River Labs (CRL) PT Raised to $300 at TD Cowen
$300.00
(was $269.64)
Piper Sandler
Charles River price target raised to $264 from $230 at Mizuho
$264.00
(was $267.49)
Mizuho Securities
Charles River price target raised to $300 from $260 at Morgan Stanley
$300.00
(was $264.05)
Morgan Stanley
Charles River price target raised to $291 from $255 at Baird
$291.00
(was $258.93)
Robert W. Baird
Charles River price target raised to $282 from $215 at RBC Capital
$282.00
(was $260.72)
RBC Capital
Charles River price target raised to $300 from $220 at Barclays
$300.00
(was $260.72)
Barclays
Charles River price target raised to $230 from $192 at Mizuho
$230.00
(was $233.41)
Mizuho Securities
Charles River price target raised to $260 from $220 at Morgan Stanley
$260.00
(was $223.96)
Morgan Stanley
Charles River Labs (CRL) PT Raised to $250 at Argus
$250.00
(was $226.79)
Bernstein
Charles River Labs (CRL) PT Raised to $250 at Argus
$250.00
(was $226.79)
BNP Paribas
Charles River upgraded to Overweight from Equal Weight at Morgan Stanley
$220.00
(was $184.79)
Morgan Stanley
Charles River upgraded to Outperform from Hold at CLSA
$219.00
(was $181.34)
CLSA
Charles River price target raised to $213 from $200 at Baird
$213.00
(was $175.56)
Eric Coldwell
·
Robert W. Baird
Charles River price target raised to $220 from $200 at Evercore ISI
$220.00
(was $176.32)
Evercore ISI
Charles River price target raised to $192 from $175 at Mizuho
$192.00
(was $181.68)
Mizuho Securities
Charles River price target raised to $220 from $210 at Barclays
$220.00
(was $181.68)
Luke Sergott
·
Barclays
Charles River price target raised to $210 from $200 at Barclays
$210.00
(was $178.34)
Luke Sergott
·
Barclays
Charles River initiated with an Outperform at RBC Capital
$215.00
(was $178.34)
RBC Capital
Charles River price target lowered to $175 from $215 at Mizuho
$175.00
(was $164.24)
Mizuho Securities
Charles River price target lowered to $193 from $231 at Baird
$193.00
(was $158.18)
Eric Coldwell
·
Robert W. Baird